Abstract
p-Aminophenol (AP) is the key intermediate of the traditional synthesis of paracetamol. The method of obtaining AP included a selective reduction reaction of the generation of N-arylhydroxylamine (AHA) using nitrobenzene (NB) as the raw material, followed by a Bamberger rearrangement reaction to transfer AHA to the target product. The generation of AHA is a key step, but due to its structural instability and the incompatibility of the two reaction systems, one-pot synthesis of paracetamol faces great challenges. Considering that using flow reactors in series may avoid the problems faced by batch reactors, the article presents the strategy to obtain paracetamol via a continuous flow technology. In particular, we focus on condition screening in total synthesis experiments, including hydrogenation, Bamberger rearrangement, and amidation in flow. The continuous three-step synthesis process used NB as a raw material to generate AHA, which entered the downstream for timely conversion, achieving in situ on-demand preparation of the unstable intermediate AHA, avoiding cumbersome processing and storage processes. Moreover, each step of the reaction system exhibits excellent compatibility, and the work-up is simple.
Introduction
The industrial production of paracetamol typically relies on p-aminophenol (AP) as a primary intermediate. A promising route to AP involves the selective reduction of nitrobenzene (NB) to N-arylhydroxylamine (AHA), which then undergoes a Bamberger rearrangement. However, AHA is notoriously unstable and prone to oxidation into unwanted azoxy compounds, making it a "problem child" in organic synthesis.
In traditional batch processing, a "one-pot" synthesis is hindered by the chemical incompatibility of the required environments: catalytic hydrogenation to form AHA thrives in neutral or slightly basic conditions, whereas the Bamberger rearrangement requires a strong acid. This usually necessitates the isolation and storage of the unstable AHA, leading to safety risks and yield losses.
Continuous Flow Methodology
To overcome these challenges, researchers developed a modular continuous flow system consisting of three integrated reaction zones. This approach allows for the "on-demand" preparation and immediate consumption of AHA, preventing degradation.
- Hydrogenation: NB is reduced to AHA in a THF solution using a 5 wt.% Pt/C catalyst cartridge. The addition of 4-(dimethylamino)pyridine (DMAP) as a mediator significantly improves both catalytic activity and selectivity for AHA.
- Bamberger Rearrangement: The AHA stream is mixed with aqueous sulfuric acid ($H_2SO_4$) in a stainless steel tube reactor. The acid serves a dual role: it neutralizes the DMAP from the first step and catalyzes the rearrangement of AHA into AP.
- Amidation: The resulting AP stream is mixed with acetic anhydride to produce the final paracetamol product.
The team utilized T-shape mixers and coiled tube reactors to maintain precise control over residence times and temperatures. Optimization was conducted through extensive screening of solvents, temperatures, and flow rates, with monitoring performed via HPLC and $^1$H NMR spectroscopy.
Key Insights and Results
The study revealed several critical factors for successful synthesis:
- Selectivity Control: The use of DMAP in the hydrogenation step was pivotal, pushing AHA selectivity to over 98%. However, this selectivity is highly sensitive to residence time; increasing it from 12 to 60 seconds caused selectivity to drop to 79.1%.
- System Compatibility: A major advantage of this flow architecture is the inherent compatibility between stages. The sulfuric acid required for the second step naturally neutralizes the DMAP from the first, allowing for a seamless transition without intermediate purification.
- Performance Metrics: Under optimal conditions (20°C for hydrogenation, 85°C for rearrangement, and 60°C for amidation), the integrated system ran steadily for 4 hours. Starting with 1.48g of nitrobenzene, the researchers produced 1.56g of paracetamol, representing an 86% overall yield with a high purity of 99.3%.
Discussion and Future Outlook
While the flow process demonstrates high efficiency and pharmaceutical-grade purity, some trade-offs were identified. For instance, while Ethyl Acetate (EtOAc) would simplify final work-up, it yielded lower selectivity (92.7%) compared to THF (98.2%).
Future work will focus on scaling these experiments to industrial throughput and assessing the long-term stability of the Pt/C catalyst cartridge. Nonetheless, this research provides a robust proof-of-concept for the continuous, on-demand synthesis of complex pharmaceuticals involving unstable intermediates.
Summary updated